Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 23, 2014, Pages 8571-8576

  Mazor, Ronit ^a,b   Eberle, Jaime A ^a,d   Hu, Xiaobo ^a,e   Vassall, Aaron N ^a,f   Onda, Masanori ^a   Beers, Richard ^a   Lee, Elizabeth C ^a,g   Kreitman, Robert J ^a   Lee, Byungkook ^a   Baker, David ^c   King, Chris ^c   Hassan, Raffit ^a   Benhar, Itai ^b   Pastan, Ira ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b TEL AVIV UNIVERSITY   (Israel)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d Thoracic and Gastrointestinal Oncology National Cancer Institute National Institutes of Health ^*  (United States)

^e UNIVERSITY OF SOUTH CHINA   (China)

^f YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Deimmunization; Protein engineering

Indexed keywords

EPITOPE; IMMUNOTOXIN; PSEUDOMONAS EXOTOXIN; RECOMBINANT IMMUNOTOXIN; T LYMPHOCYTE ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER THERAPY; CONTROLLED STUDY; DRUG CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TOXIN ANALYSIS;

DEIMMUNIZATION; PROTEIN ENGINEERING;

ADP RIBOSE TRANSFERASES; AMINO ACIDS; ANIMALS; ANTIBODY FORMATION; BACTERIAL TOXINS; CELL LINE, TUMOR; CELL SURVIVAL; ELECTROPHORESIS, POLYACRYLAMIDE GEL; EPITOPE MAPPING; EPITOPES, T-LYMPHOCYTE; EXOTOXINS; FEMALE; HUMANS; IMMUNOTHERAPY; IMMUNOTOXINS; LYMPHOCYTE ACTIVATION; MICE; MICE, SCID; MODELS, MOLECULAR; NEOPLASMS; PEPTIDES; POINT MUTATION; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES; VIRULENCE FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84902202498     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1405153111     Document Type: Article

References (30)

1. Kreitman RJ, Pastan I (2011) Antibody fusion proteins: Anti-CD22 recombinant immunotoxin moxetumomab pasudotox. Clin Cancer Res 17(20):6398-6405.
2. Kreitman RJ, et al. (2012) Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol 30(15):1822-1828.
3. Reichert JM (2013) Antibodies to watch in 2013: Mid-year update. MAbs 5(4):513-517.
4. Chirino AJ, Ary ML, Marshall SA (2004) Minimizing the immunogenicity of protein therapeutics. Drug Discov Today 9(2):82-90. (Pubitemid 38169532)
5. De Groot AS, Scott DW (2007) Immunogenicity of protein therapeutics. Trends Immunol 28(11):482-490. (Pubitemid 350087812)
6. Hassan R, et al. (2007) Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res 13(17):5144-5149. (Pubitemid 47502082)
7. Kreitman RJ, Hassan R, Fitzgerald DJ, Pastan I (2009) Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. Clin Cancer Res 15(16):5274-5279.
8. Kindt TJ, Osborne BA, Goldsby RA, eds (2000) Kuby Immunology (W. H. Freeman, New York), 6th Ed.
9. Parker DC (1993) T cell-dependent B cell activation. Annu Rev Immunol 11:331-360.
10. Yeung VP, et al. (2004) Elimination of an immunodominant CD4+ T cell epitope in human IFN-beta does not result in an in vivo response directed at the subdominant epitope. J Immunol 172(11):6658-6665. (Pubitemid 38669101)
11. Tangri S, et al. (2005) Rationally engineered therapeutic proteins with reduced immunogenicity. J Immunol 174(6):3187-3196. (Pubitemid 40354020)
12. Mazor R, et al. (2012) Identification and elimination of an immunodominant T-cell epitope in recombinant immunotoxins based on Pseudomonas exotoxin A. Proc Natl Acad Sci USA 109(51):E3597-E3603.
13. Chowdhury PS, Pastan I (1999) Improving antibody affinity by mimicking somatic hypermutation in vitro. Nat Biotechnol 17(6):568-572. (Pubitemid 29262920)
14. Weldon JE, et al. (2009) A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity. Blood 113(16):3792-3800.
15. Wang P, et al. (2008) A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach. PLOS Comput Biol 4(4):e1000048.
16. Wedekind JE, et al. (2001) Refined crystallographic structure of Pseudomonas aeruginosa exotoxin A and its implications for the molecular mechanism of toxicity. J Mol Biol 314(4):823-837. (Pubitemid 34087850)
17. King C, et al. (2014) Removing T-cell epitopes with computational protein design. Proc Natl Acad Sci USA 111(23):8577-8582.
18. Lee B, Richards FM (1971) The interpretation of protein structures: Estimation of static accessibility. J Mol Biol 55(3):379-400.
19. Roscoe DM, et al. (1994) Primate antibody response to immunotoxin: Serological and computer-aided analysis of epitopes on a truncated form of Pseudomonas exotoxin. Infect Immun 62(11):5055-5065. (Pubitemid 24332815)
20. Weldon JE, et al. (2013) A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicity. Mol Cancer Ther 12(1):48-57.
21. Oseroff C, et al. (2010) Molecular determinants of T cell epitope recognition to the common Timothy grass allergen. J Immunol 185(2):943-955.
22. De Rosa SC, et al. (2004) Vaccination in humans generates broad T cell cytokine responses. J Immunol 173(9):5372-5380. (Pubitemid 39392120)
23. Kwok WW, et al. (2012) Frequency of epitope-specific naive CD4(+) T cells correlates with immunodominance in the humanmemory repertoire. J Immunol 188(6):2537-2544.
24. Harding FA (2008). US Patent 0153976.
25. Allured VS, Collier RJ, Carroll SF, McKay DB (1986) Structure of exotoxin A of Pseudomonas aeruginosa at 3.0-Angstrom resolution. Proc Natl Acad Sci USA 83(5):1320-1324. (Pubitemid 16016120)
26. Liu Z, Williams KP, Chang YH, Smith JA (1993) Immunodominance: A single amino acid substitution within an antigenic site alters intramolecular selection of T cell determinants. J Immunol 151(4):1852-1858. (Pubitemid 23235658)
27. Liu W, et al. (2012) Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes. Proc Natl Acad Sci USA 109(29):11782-11787.
28. Wang P, et al. (2010) Peptide binding predictions for HLA DR, DP and DQ molecules. BMC Bioinformatics 11:568.
29. Pastan I, Beers R, Bera TK (2004) Recombinant immunotoxins in the treatment of cancer. Methods Mol Biol 248:503-518.
30. Onda M, et al. (2011) Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes. Proc Natl Acad Sci USA 108(14):5742 - 5747.